These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/ Bill M; Mrózek K; Kohlschmidt J; Eisfeld AK; Walker CJ; Nicolet D; Papaioannou D; Blachly JS; Orwick S; Carroll AJ; Kolitz JE; Powell BL; Stone RM; de la Chapelle A; Byrd JC; Bloomfield CD Proc Natl Acad Sci U S A; 2020 Oct; 117(42):26340-26346. PubMed ID: 33020282 [TBL] [Abstract][Full Text] [Related]
11. A New Complex Karyotype Involving a KMT2A-r Variant Three-Way Translocation in a Rare Clinical Presentation of a Pediatric Patient with Acute Myeloid Leukemia. Capela de Matos RR; Ney Garcia DR; Othman MAK; Moura Ferreira G; Melo JB; Carreira IM; Meyer C; Marschalek R; Costa ES; Land MGP; Liehr T; Ribeiro RC; Silva MLM Cytogenet Genome Res; 2019; 157(4):213-219. PubMed ID: 30974445 [TBL] [Abstract][Full Text] [Related]
13. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements. Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755 [TBL] [Abstract][Full Text] [Related]
14. Umbilical cord blood transplantation can overcome the poor prognosis of KMT2A-MLLT3 acute myeloid leukemia and can lead to good GVHD-free/relapse-free survival. Tong J; Zhang L; Liu H; Xu X; Zheng C; Yao W; Zhu X; Tang B; Wan X; Song K; Zhang X; Sun G; Sun Z Ann Hematol; 2021 May; 100(5):1303-1309. PubMed ID: 33469688 [TBL] [Abstract][Full Text] [Related]
16. Recent Developments and Evolving Therapeutic Strategies in KMT2A-Rearranged Acute Leukemia. Yin L; Wan L; Zhang Y; Hua S; Shao X Cancer Med; 2024 Oct; 13(20):e70326. PubMed ID: 39428967 [TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630 [TBL] [Abstract][Full Text] [Related]
18. Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML. Matsuo H; Yoshida K; Nakatani K; Harata Y; Higashitani M; Ito Y; Kamikubo Y; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Okada A; Nannya Y; Takeda J; Ueno H; Kiyokawa N; Tomizawa D; Taga T; Tawa A; Miyano S; Meggendorfer M; Haferlach C; Ogawa S; Adachi S Blood Adv; 2020 Oct; 4(19):4623-4631. PubMed ID: 32991719 [TBL] [Abstract][Full Text] [Related]
19. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312 [TBL] [Abstract][Full Text] [Related]